证券代码：300753 证券简称：爱朋医疗 公告编号：2024-029 江苏爱朋医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于2024年4月24日召开了第 三届董事会第七次会议，于2024年5月20日召开了2023年年度股东大会，分别审议通 过了《关于修订<公司章程>的议案》，具体内容详见公司于中国证监会指定的信息披 露网站巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 公司已于近日完成了相关工商变更登记及备案手续，并取得了由南通市行政审批 局换发的《营业执照》，具体信息如下： 一、公司新换发的《营业执照》相关信息： 1、名称：江苏爱朋医疗科技股份有限公司 2、统一社会信用代码：9132062372933999XT 3、类型：股份有限公司（上市） 4、住所：如东县经济开发区永通大道东侧 关于完成工商变更登记并换发营业执照的公告 6、注册资本：12604.8万元整 7、成立日期：2001年10月30日 8、经营范围：许可项目：第三类医疗器械生产；第三类医疗器械经营；第二类 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-028 江苏爱朋医疗科技股份有限公司 2023年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）2023年年度权益分派方案已 获2024年5月20日召开的2023年年度股东大会审议通过。现将权益分派事宜公告如下： 一、股东大会审议通过的权益分派方案情况 1、公司于2024年5月20日召开了2023年年度股东大会，审议通过了《2023年度利 润分配预案》，具体方案为：以2023年12月31日公司总股本126,048,000股为基数，向 全体股东每10股派发现金红利0.65元（含税），合计派发现金红利819.312万元，不送 红股，不以资本公积金转增股本。若在利润分配方案实施前，公司总股本发生变动， 将按照"现金分红总额固定不变"的原则，在利润分配实施公告中披露按公司最新总 股本计算的分配比例。 2、自上述分派方案披露日至本公告日，公司股本总额未发生变化。 3、本次实施的权益分派方案与公司2023年年度股东大会审议通过的分配方案及 ...

上海国瓴律师事务所 关于 江苏爱朋医疗科技股份有限公司 2023 年年度股东大会见证的 法律意见 上海国瓴律師事務所 SHANGHAIGUOLINGLAWFIRM 上海市闵行区秀文路 898 号西子国际中心 2 号楼 3 楼/徐汇区衡山路 598 号 电话：021-33883626 传真：021-34127367 网址：www.guolinglaw.com 2023 年年度股东大会见证的法律意见 上海国瓴律师事务所 关于 江苏爱朋医疗科技股份有限公司 2023 年年度股东大会见证的 法律意见 国瓴 2024009-2 号 致：江苏爱朋医疗科技股份有限公司 上海国瓴律师事务所（以下简称"本所"）受江苏爱朋医疗科技股份有限公 司（以下简称"公司"）委托，指派朱琴律师和曹一坤律师（以下合称"本所律 师"）出席公司 2023 年年度股东大会（以下简称"本次股东大会"），对本次 股东大会召开的合法性进行见证并出具本法律意见。 本所律师依据本法律意见出具日前已经发生或存在的事实和《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《上市公司股东大会规则（2022 年 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-025 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于2024年4月24日召开 了第三届董事会第七次会议，审议通过了《关于选举公司董事的议案》，关继峰先 生因个人原因，申请辞去公司第三届董事会董事、战略委员会委员职务，辞职后关 继峰先生不再担任公司任何职务。为保障董事会工作的正常运作，根据《公司法》 《深圳证券交易所创业板股票上市规则》等法律法规及《公司章程》的规定，公司 董事会提名CHENG JUNPEI（程俊佩）女士（简历附后）为公司第三届董事会非独 立董事候选人及战略委员会委员，任期自公司2023年年度股东大会审议通过之日起 至公司第三届董事会届满之日止。 公司于2024年5月20日召开2023年年度股东大会，审议通过了《关于选举公司 董事的议案》，同意选举CHENG JUNPEI（程俊佩）女士为公司第三届董事会非独 立董事及战略委员会委员，任期自公司2023年年度股东大会审议通过之日起至公司 第三届董事会届满之日止。 特此公告。 江苏爱朋 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-025 江苏爱朋医疗科技股份有限公司 2023年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决议案的情形； 2、本次股东大会未涉及变更前次股东大会决议的情形； 3、本次股东大会采取现场投票与网络投票相结合的方式召开； 4、本次股东大会所有议案对中小股东表决单独计票。 一、会议的召开情况 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2024年5月20日9:15至9:25，9:30至11:30，13:00至15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为：2024年5月20日9:15至15:00。 2、现场会议召开地点：上海市闵行区联航路1188号3号楼公司会议室。 3、会议表决方式：现场表决与网络投票相结合的方式 4、会议召集人：江苏爱朋医疗科技股份有限公司董事会 5、会议主持人：董事长王凝宇先生 6、会议召开的合法、合规性：本次股东大会会议召开符合《中华人民共和国公 - 1 - 司法》 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-027 江苏爱朋医疗科技股份有限公司 关于股东回馈活动的自愿性信息披露公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）自成立至今，一直耕耘 于疼痛管理、鼻腔及上气道管理细分领域用医疗器械产品，积极践行"舒适化医 疗"。为建立长效股东回报机制，答谢各位股东长期以来对公司的关心和支持，公 司决定开展"守护鼻腔健康·爱朋医疗股东回馈活动"，现将活动内容公告如下： 一、参加活动的股东范围 2024年5月10日（公司2023年年度股东大会登记日）15:00收市后当日在中国证 券登记结算有限责任公司登记在册的持有本公司股票的所有股东。 二、活动具体内容 为回馈长期以来支持公司的投资者，本次活动期间内符合条件的股东可同时参 与以下两项活动，也可选择一项参加。具体活动内容如下： 1、活动一： 2024年5月10日收市后登记在册的持有本公司股票的所有股东可免费领取诺斯 清®生理性海水鼻腔护理喷雾器儿童装3瓶或4瓶（规格可选等渗款/高渗款/弱酸款） 及敏伴®保湿纸 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-024 江苏爱朋医疗科技股份有限公司 关于举行2023年度暨2024年第一季度网上业绩说明会的公告 为了便于投资者更全面地了解公司2023年度及2024年第一季度经营情况，公司定 于2024年5月21日（星期二）15:00-16:30 举行2023年度暨2024年第一季度网上业绩说明 会，本次业绩说明会将通过深圳证券交易所提供的"互动易"平台举行，投资者可登 陆"互动易" 网站（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业绩说 明会。 出席本次业绩说明会的人员有：公司董事长王凝宇先生、副总经理兼财务总监袁 栋麒先生、副总经理兼董事会秘书缪飞先生、独立董事侯利阳先生（如遇特殊情况， 参会人员可能进行调整）。 为充分尊重投资者，提升公司与投资者的交流效率和针对性，现就公司本次业绩 说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登 录深圳证券交易所互动易平台（http://irm.cninfo.com.cn）"云访谈"栏目，进入问题 征集专题页面进行提问。公司将在本次业绩说明会上，在信息披露 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥87,752,962, a decrease of 6.71% compared to ¥94,068,177 in the same period last year[5] - Net profit attributable to shareholders increased by 11.63% to ¥1,356,953.49 from ¥1,215,574.66 year-on-year[5] - The net profit after deducting non-recurring gains and losses surged by 76.41% to ¥1,720,177.95 compared to ¥975,082.81 in the previous year[5] - Net profit for Q1 2024 was CNY 1,127,308.15, a decrease of 9.8% from CNY 1,250,235.16 in Q1 2023[24] - Total operating revenue for Q1 2024 was CNY 87,752,962, a decrease of 6.0% compared to CNY 94,068,177.53 in Q1 2023[23] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥64,053,023.05, slightly worse than -¥60,865,461.63 in the same period last year, reflecting a decline of 5.24%[5] - The company's cash and cash equivalents decreased significantly by 76.13% to ¥47,944,359.60 due to investments in financial products[10] - The cash flow from financing activities showed a net inflow of ¥8,339,252.52, compared to a net outflow of ¥1,463,619.19 in the previous year[27] - The total cash and cash equivalents at the end of the period were ¥47,944,359.60, a decrease from ¥200,896,344.58 at the beginning of the period[27] - The cash and cash equivalents net increase was -¥152,951,984.98, compared to -¥205,250,243.54 in the same period last year[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥843,679,848.99, down 1.85% from ¥859,572,978.63 at the end of the previous year[5] - The total liabilities decreased to CNY 145,266,713.67 from CNY 162,377,151.47, reflecting a reduction of 10.5%[24] - The total current liabilities decreased to CNY 112,087,318.16 from CNY 129,873,385.02, a reduction of about 13.7%[20] - The total non-current assets amounted to CNY 413,540,432.67, slightly down from CNY 417,269,663.85[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,868[12] - The company reported a total of 45,053,063 shares under lock-up agreements, with a planned release date of August 6, 2025[16] - The company plans to increase its shareholding by at least CNY 5.4 million within six months from February 6, 2024, using self-raised funds[17] Operational Metrics - The company's cash received from sales of goods and services was CNY 69,016,477.25, down 13.8% from CNY 80,064,517.56 in Q1 2023[25] - Research and development expenses were CNY 7,677,023.64, down 20.7% from CNY 9,687,121.04 in Q1 2023[24] - Sales expenses decreased to CNY 24,765,360.77, a reduction of 21.0% from CNY 31,384,618.87 in the previous year[24] - Accounts receivable increased to CNY 162,468,844.13 from CNY 148,402,423.90, reflecting a growth of approximately 9.5%[19] - The company's inventory rose to CNY 59,059,390.73 from CNY 55,688,087.49, representing an increase of about 4.9%[19] - Short-term borrowings increased to CNY 49,237,875.14 from CNY 39,237,875.14, showing a rise of approximately 25.5%[20] Other Income and Expenses - Other income dropped by 82.84% to ¥1,263,464.93, primarily due to the absence of tax refunds[10] - Total operating costs decreased to CNY 86,636,436.82, down 12.5% from CNY 99,122,242.30 in the previous year[23] - The company distributed dividends and profits amounting to ¥332,166.81, slightly up from ¥322,328.19 year-over-year[27] - The cash outflow from financing activities totaled ¥1,750,747.48, a significant decrease from ¥11,363,619.19 in the previous year[27] Regulatory and Compliance - The company has not undergone an audit for the first quarter report[28] - Jiangsu Aipeng's subsidiary, Sichuan Jinjiazheng Medical Equipment Co., Ltd., received a medical device registration certificate for a third-class anesthesia depth monitor on February 5, 2024[17]

Financial Performance - The company's operating revenue for 2023 reached ¥422,170,460.93, representing a 30.38% increase compared to ¥323,808,133.90 in 2022[20]. - The net profit attributable to shareholders was ¥8,277,352.58, a significant turnaround from a loss of ¥76,377,405.54 in the previous year, marking a 110.89% improvement[20]. - The net profit after deducting non-recurring gains and losses was ¥4,835,442.71, compared to a loss of ¥82,281,748.42 in 2022, reflecting a 105.91% increase[20]. - The basic earnings per share improved to ¥0.0657 from a loss of ¥0.6059 in 2022, indicating a 110.89% increase[20]. - The total assets at the end of 2023 were ¥859,572,978.63, a decrease of 1.28% from ¥870,213,234.55 in 2022[20]. - The net assets attributable to shareholders increased by 1.50% to ¥696,203,485.91 from ¥685,580,361.21 in 2022[20]. - The company reported a net cash flow from operating activities of -¥23,335,844.92, an improvement of 5.12% from -¥24,593,930.44 in the previous year[20]. - The weighted average return on net assets was 1.20%, recovering from -10.43% in 2022[20]. - The company achieved total operating revenue of CNY 422.17 million, representing a year-on-year growth of 30.38%[61]. - The net profit attributable to shareholders of the listed company was CNY 8.28 million, an increase of 110.89% compared to the same period last year[61]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 4.84 million, up 105.91% year-on-year[61]. Market and Product Development - The company is focused on expanding its market presence and enhancing its product offerings through research and development initiatives[12]. - The company is focused on developing new products, including various infusion and anesthesia monitoring devices, to enhance its market position[20]. - The company is implementing strategies for market expansion and technological innovation to drive future growth[20]. - The company has established several private equity investment funds, indicating a strategy for financial diversification and investment in growth opportunities[12]. - The company is actively developing nasal cavity and upper airway management solutions, with products for various nasal diseases and sleep monitoring[55]. - The company is expanding its chronic pain management product line, including heat needle therapy devices, low-frequency therapy devices, and shock wave therapy devices[52]. - The company is exploring new consumer products in the fast recovery and medical beauty sectors, with a focus on perioperative management and recovery[59]. - The company is enhancing its innovation capabilities by incubating medical devices and optimizing resource allocation for industry development[59]. - The company is focusing on developing a closed-loop anesthesia system, which is expected to enhance its technological barriers in the market[113]. - The company is focusing on integrating advanced monitoring systems to support clinical data management and improve patient monitoring capabilities[116]. Strategic Initiatives and Investments - The company has established a clear strategy for capital allocation, including reinvestment into its core business areas and potential acquisitions to drive growth[12]. - The company has made significant advancements in pain assessment algorithms, utilizing machine learning and deep learning techniques[113]. - The company has established partnerships with multiple universities, achieving breakthroughs in pain management and anesthesia technology[74]. - The company has invested in Changzhou Ruishen'an Medical Equipment Co., which specializes in brain-machine interface technology and has developed products for epilepsy and pain treatment[53]. - The company has established a national-level postdoctoral research station and a provincial graduate work station to support talent development and technological innovation[93]. - The company plans to invest a total of CNY 26,293 million in various projects, with CNY 4,434.49 million allocated to the industrial base upgrade and CNY 18,078.98 million to the R&D center construction[148]. - The company has decided to terminate the marketing network construction project and reallocate the funds to the industrial base upgrade and R&D center projects to optimize financial structure and reduce risks[148]. - The company is focusing on creating greater value for shareholders by improving the efficiency of fund usage and financial structure[148]. Regulatory Compliance and Governance - The company is committed to complying with the disclosure requirements for medical device businesses as per the Shenzhen Stock Exchange guidelines[4]. - The company emphasizes the importance of risk awareness regarding future plans and development strategies, urging investors to understand the differences between plans, forecasts, and commitments[4]. - The report outlines the company's governance structure and commitment to environmental and social responsibilities, reflecting its corporate values[5]. - The company maintains transparency in information disclosure, ensuring that all investors have equal access to timely and accurate information[182]. - The company emphasizes the importance of investor relations management, appointing the board secretary as the responsible person for managing investor communications[183]. - The company has established independent financial and accounting systems, ensuring no interference from controlling shareholders[185]. - The company has a dedicated talent development department to manage human resources independently from its controlling shareholders[185]. Market Trends and Opportunities - The market for pain management devices is projected to grow at a compound annual growth rate (CAGR) of 13.8%, reaching a market size of 14.55 billion by 2026[32]. - The demand for "comfort healthcare" is increasing, driven by societal development and rising living standards, indicating a growing market opportunity for the company[31]. - The number of surgical procedures in China reached 82.72 million in 2022, with a CAGR of about 10%, highlighting a significant demand for postoperative pain management solutions[34]. - The company has identified a growing need for nasal care devices due to the rising incidence of upper respiratory infections, with 110.01 million ENT visits recorded in 2021[35]. - The global prevalence of sleep disorders is approximately 27%, with over 300 million individuals in China affected by sleep issues[36]. - The Chinese government has included sleep health in the "Healthy China Action (2019-2030)" initiative, indicating a growing market opportunity in sleep healthcare[36]. - The domestic medical device procurement policy has favored local manufacturers, leading to a significant increase in their winning bids[38]. Research and Development - The company reported a research and development investment of ¥36,549,133.77 in 2023, accounting for 8.66% of its operating revenue, a decrease from 10.79% in 2022[114]. - The number of R&D personnel decreased by 17.92% from 106 in 2022 to 87 in 2023, with a notable drop in the number of personnel holding master's degrees, down by 31.82%[114]. - The company has established a comprehensive quality control system covering all stages from R&D to after-sales, ensuring high product quality and compliance with ISO9001 and ISO13485 standards[95]. - The company is committed to ongoing research and development to enhance its product offerings and maintain a competitive edge in the medical technology market[116]. Corporate Social Responsibility - The company actively participates in public welfare while balancing the interests of shareholders, employees, and society[184]. - The company has been recognized as a "National Intellectual Property Advantage Enterprise" and a "National Employment and Social Security Advanced Private Enterprise" in 2023[44]. - The company has established a strong brand and channel advantage in the nasal care market, with its nasal care products leading in sales on platforms like Tmall and JD.com[91].

第一章 总 则 第一条 为规范江苏爱朋医疗科技股份有限公司（以下简称"公司"）监事 会的议事方式和决策程序，促使监事和监事会有效地履行职责，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司治理准则》《深圳证券交易 所创业板股票上市规则》等有关法律、法规、规范性文件和《江苏爱朋医疗科技股 份有限公司章程》（以下简称"《公司章程》"）之规定制定本规则。 江苏爱朋医疗科技股份有限公司 监事会议事规则 第二条 监事会是公司的监督机构，向全体股东负责，以财务监督为核心， 根据《公司法》及其他有关法律、法规、规范性文件和《公司章程》的规定，对公 司财务以及公司董事、总经理和其他高级管理人员履行职责的合法、合规性进行监 督，维护公司及股东的合法权益。 监事会共 3 人，由股东监事与职工代表监事组成。其中职工代表监事由职工代表 大会或者其他形式民主选举产生。监事会设监事会主席 1 人，监事会主席由全体监 事过半数选举产生。 监事应当具有相应的专业知识或者工作经验，具备有效履职能力。公司董事、高 级管理人员不得兼任监事。董事、高级管理人员在任期间其配偶和直系亲属不得担 任公司监事。 第三条 监事会主席负责处理 ...